Login Register Cart 0
Generic placeholder image

Drug Delivery Letters

Editor-in-Chief

ISSN (Print): 2210-3031
ISSN (Online): 2210-304X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Estimation of Human Oral Fraction Dose Absorbed of Simvastatin from Various Formulations using in-situ Single Pass Intestinal Perfusion Method

Author(s): Madhu Verma*, Arun Nanda, Iti Chauhan, Mohd. Yasir, Sagarika Majhi, Rajkumari and Meenakshi Sharma

Volume 13, Issue 4, 2023

Published on: 30 May, 2023

Page: [283 - 295] Pages: 13

DOI: 10.2174/2210303113666230502150257

Price: $65

conference banner
Abstract

Background: SIM is a poorly water-soluble drug with dissolution-dependent bioavailability. A solid dispersion and self-emulsifying drug delivery system was developed, optimized, and evaluated to improve its bioavailability. The permeability coefficient in rats was determined using the in-situ single-pass intestinal perfusion (SPIP) technique. Further, the permeability coefficient (Peff, humans) was used to calculate the permeability and fraction of SIM bioavailable to humans which have not yet been reported for these formulations.

Objective: To estimate and compare various formulations of Simvastatin (SIM) for bioavailable fraction to humans (Fa) as a function of solubility enhancement.

Methods: In this study, the preparation and evaluation of SIM formulations i.e., Self-emulsifying drug delivery system (SEDDS) and Solid dispersions (SD) are discussed in brief. An uncomplicated, precise, and accurate HPLC method was validated for simultaneous determination of SIM and phenol red as per ICH guidelines. A comparative in-vitro dissolution test, pharmacokinetic studies, and in-situ SPIP technique in rats were carried out amongst optimized formulations of SIM-SD and SIM-SEDDS, SIM suspension (SIM-SUSP), and SIM marketed preparation (SIM-MP).

Results: The HPLC method was successfully validated. In-vitro dissolution test displays that both the SIM formulations i.e., SIM-SEDDS and SIM-SD shows better dissolution rate than SIM-MP and SIM-SUSP. Pharmacokinetic studies revealed that SIM-SEDDS, SIM-SD, and SIM-MP showed significant differences when compared to SIM-SUSP in terms of Cmax, [AUC] 0-∞, at P ≤ 0.05. The comparison of permeability coefficient between SIM SEDDS vs. SIM MP and SIM SEDDS vs. SIM SD were non-significant. In contrast, SIM- SUSP vs. all other formulations were significantly different at P ≤ 0.05 (employing two-way ANOVA followed by post-Bonferroni Test). Fa for SIM SUSP, an optimized formulation of SIM-SEDDS, SIM-MP, and SIM-SD are 0.353, 0.977, 0.975, and 0.987 respectively. It is revealed that SIM-SEDDS and SIM-SD showed enhanced absorption and the results are confirmed by in-vitro data, pharmacokinetic studies, and In-situ SPIP techniques.

Conclusion: The permeability prediction method is a rapid and economical method for screening chemical compounds with the least possible utilization of resources. So, its use can be extended in prime and initial screening prototypes for the evaluation of compounds in the early stages of their formulations.

Keywords: Single pass intestinal perfusion method, solubility enhancement, simvastatin, self-emulsifying drug delivery system, solid dispersion, two-way ANOVA, bonferroni test.

« Previous Next »
Graphical Abstract

[1]
Balimane, P.V.; Chong, S.; Morrison, R.A. Current methodologies used for evaluation of intestinal permeability and absorption. J. Pharmacol. Toxicol. Methods, 2000, 44(1), 301-312.
[http://dx.doi.org/10.1016/S1056-8719(00)00113-1] [PMID: 11274897]
[2]
Amidon, G.L.; Lennernäs, H.; Shah, V.P.; Crison, J.R. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 1995, 12(3), 413-420.
[http://dx.doi.org/10.1023/A:1016212804288] [PMID: 7617530]
[3]
Lennernäs, H. Animal data: The contributions of the Ussing Chamber and perfusion systems to predicting human oral drug delivery in vivo. Adv. Drug Deliv. Rev., 2007, 59(11), 1103-1120.
[http://dx.doi.org/10.1016/j.addr.2007.06.016] [PMID: 17900749]
[4]
Martinez, M.N.; Amidon, G.L. A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals. J. Clin. Pharmacol., 2002, 42(6), 620-643.
[http://dx.doi.org/10.1177/00970002042006005] [PMID: 12043951]
[5]
Wu, C.Y.; Benet, L.Z. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res., 2005, 22(1), 11-23.
[http://dx.doi.org/10.1007/s11095-004-9004-4] [PMID: 15771225]
[6]
Guidance for industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage formsbased on a biopharmaceutics classification system, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) 2000. Available From : www.fda.gov/AboutFDA/CentersOffices/CDER/ucm128219.htm
[7]
Dahan, A.; West, B.T.; Amidon, G.L. Segmental-dependent membrane permeability along the intestine following oral drug administration: Evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur. J. Pharm. Sci., 2009, 36(2-3), 320-329.
[http://dx.doi.org/10.1016/j.ejps.2008.10.013] [PMID: 19028572]
[8]
Schanker, L.S.; Tocco, D.J.; Brodie, B.B.; Hogben, C.A. Absorption of drugs from the rat small intestine. J. Pharmacol. Exp. Ther., 1958, 123(1), 81-88.
[PMID: 13539795]
[9]
Lozoya-Agullo, I.; Zur, M.; Wolk, O.; Beig, A.; González-Álvarez, I.; González-Álvarez, M.; Merino-Sanjuán, M.; Bermejo, M.; Dahan, A. In-situ intestinal rat perfusions for human Fabs prediction and BCS permeability class determination: Investigation of the single-pass vs. the Doluisio experimental approaches. Int. J. Pharm., 2015, 480(1-2), 1-7.
[http://dx.doi.org/10.1016/j.ijpharm.2015.01.014] [PMID: 25595387]
[10]
Zakeri-Milani, P.; Barzegar-Jalali, M.; Azimi, M.; Valizadeh, H. Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability. Eur. J. Pharm. Biopharm., 2009, 73(1), 102-106.
[http://dx.doi.org/10.1016/j.ejpb.2009.04.015] [PMID: 19442726]
[11]
Luo, Z.; Liu, Y.; Zhao, B.; Tang, M.; Dong, H.; Zhang, L.; Lv, B.; Wei, L. Ex vivo and in situ approaches used to study intestinal absorption. J. Pharmacol. Toxicol. Methods, 2013, 68(2), 208-216.
[http://dx.doi.org/10.1016/j.vascn.2013.06.001] [PMID: 23831587]
[12]
Sutton, S.C.; Rinaldi, M.T.S.; Vukovinsky, K.E. Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion model. AAPS PharmSci, 2001, 3(3), 93-97.
[http://dx.doi.org/10.1208/ps030325] [PMID: 11741276]
[13]
Fagerholm, U.; Johansson, M.; Lennernäs, H. Comparison between permeability coefficients in rat and human jejunum. Pharm. Res., 1996, 13(9), 1336-1342.
[http://dx.doi.org/10.1023/A:1016065715308] [PMID: 8893271]
[14]
LennernÄs H. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J. Pharm. Pharmacol., 2011, 49(7), 627-638.
[http://dx.doi.org/10.1111/j.2042-7158.1997.tb06084.x] [PMID: 9255703]
[15]
Amidon, G.L.; Sinko, P.J.; Fleisher, D. Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res., 1988, 5(10), 651-654.
[http://dx.doi.org/10.1023/A:1015927004752] [PMID: 3244618]
[16]
Cao, X.; Gibbs, S.T.; Fang, L.; Miller, H.A.; Landowski, C.P.; Shin, H.C.; Lennernas, H.; Zhong, Y.; Amidon, G.L.; Yu, L.X.; Sun, D. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res., 2006, 23(8), 1675-1686.
[http://dx.doi.org/10.1007/s11095-006-9041-2] [PMID: 16841194]
[17]
Bersot, T.P. Drug therapy for hypercholesterolemia and dyslipidemis. Goodman & Gilman’s pharmacological basis of therapeutics, 12th ed; Mcgraw-Hill: New York, 2011, pp. 877-909.
[18]
Chen, X.Q.; Cho, S.J.; Li, Y.; Venkatesh, S. Prediction of aqueous solubility of organic compounds using a quantitative structure-property relationship. J. Pharm. Sci., 2002, 91(8), 1838-1852.
[http://dx.doi.org/10.1002/jps.10178] [PMID: 12115811]
[19]
Hansch, C.; Leo, A.; Hoekman, D. Exploring QSAR - Hydrophobic, Electronic, and Steric Constants American Chemical Society: Washington, DC, 1995; p. 18.
[20]
Verma, M.; Nanda, A.; Kumar, Y. development and validation of a discriminative dissolution method for the quantification of simvastatin in different pharmaceutical formulations. Drug Deliv. Lett., 2018, 8(1), 61-71.
[http://dx.doi.org/10.2174/2210303107666171101162757]
[21]
Rathore, R.; Jain, J.P.; Srivastava, A.; Jachak, S.M.; Kumar, N. Simultaneous determination of hydrazinocurcumin and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation. J. Pharm. Biomed. Anal., 2008, 46(2), 374-380.
[http://dx.doi.org/10.1016/j.jpba.2007.09.019] [PMID: 17988818]
[22]
Cook, T.J.; Shenoy, S.S. Intestinal permeability of chlorpyrifos using the single-pass intestinal perfusion method in the rat. Toxicology, 2003, 184(2-3), 125-133.
[http://dx.doi.org/10.1016/S0300-483X(02)00555-3] [PMID: 12499115]
[23]
Shekhar, M.C.; Reddy, J.C. Effect of simvastatin on the pharmacodynamic activity of repaglinide in rats/rabbits. Int. J. Diabetes Res., 2012, 1(4), 52-57.
[http://dx.doi.org/10.5923/j.diabetes.20120104.02]
[24]
Xu, D.; Li, F.; Zhang, M.; Zhang, J.; Liu, C.; Hu, M.; Zhong, Z.; Jia, L.; Wang, D.; Wu, J.; Liu, L.; Liu, X. Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes. Acta Pharmacol. Sin., 2014, 35(9), 1215-1225.
[http://dx.doi.org/10.1038/aps.2014.39] [PMID: 25152023]
[25]
Mandal, S.; Mandal, S.S.; Sawant, K.K. Design and development of microemulsion drug delivery system of atorvastatin and study its intestinal permeability in rats. Int. J. Drug Deliv., 2010, 2(1), 69-75.
[http://dx.doi.org/10.5138/ijdd.2010.0975.0215.02014]
[26]
Yerasi, N.; Vurimindi, H.; Devarakonda, K. Frog intestinal perfusion to evaluate drug permeability: Application to p-gp and cyp3a4 substrates. Front. Pharmacol., 2015, 6, 141.
[http://dx.doi.org/10.3389/fphar.2015.00141] [PMID: 26236236]
[27]
Dezani, T.M.; Dezani, A.B.; Junior, J.B.S.; Serra, C.H.R. Single-Pass Intestinal Perfusion (SPIP) and prediction of fraction absorbed and permeability in humans: A study with antiretroviral drugs. Eur. J. Pharm. Biopharm., 2016, 104, 131-139.
[http://dx.doi.org/10.1016/j.ejpb.2016.04.020] [PMID: 27130787]
[28]
Reis, J.M.; Dezani, A.B.; Pereira, T.M.; Avdeef, A.; Serra, C.H.R. Lamivudine permeability study: A comparison between PAMPA, ex vivo and in situ Single-Pass Intestinal Perfusion (SPIP) in rat jejunum. Eur. J. Pharm. Sci., 2013, 48(4-5), 781-789.
[http://dx.doi.org/10.1016/j.ejps.2012.12.025] [PMID: 23298578]
[29]
Salphati, L.; Childers, K.; Pan, L.; Tsutsui, K.; Takahashi, L. Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man. J. Pharm. Pharmacol., 2010, 53(7), 1007-1013.
[http://dx.doi.org/10.1211/0022357011776252] [PMID: 11480535]
[30]
Zakeri-Milani, P.; Valizadeh, H.; Tajerzadeh, H.; Azarmi, Y.; Islambolchilar, Z.; Barzegar, S.; Barzegar-Jalali, M. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J. Pharm. Pharm. Sci., 2007, 10(3), 368-379.
[PMID: 17727800]

Rights & Permissions Print Cite
Article Metrics
19
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy